PASG — Passage Bio, Inc.

Passage Bio (PASG) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash Position: As of December 31, 2022, cash equivalents and marketable securities totaled $189.6 million, down from $315.8 million in 2021.
• Expenses:
  • R&D expenses were $17.7 million for Q4 2022 and $86.1 million for the full year, compared to $33 million and $117.7 million in the previous year.
  • G&A expenses were $10.6 million for Q4 and $49.3 million for the year, down from $17.2 million and $60.1 million in 2021.
• Net Loss: The net loss for Q4 was $27.1 million, and $136.1 million for the full year, an improvement from $51.2 million and $185.4 million in 2021.

2. Strategic Updates and Business Highlights:

• Clinical Programs:
  • The company is advancing its two lead programs: PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD).
  • In the Imagine-1 trial for GM1, data presented at the WORLDSymposium showed PBGM01 is well tolerated with a positive safety profile and biological effects observed in treated patients.
  • Plans to treat additional patients at a higher dose and revise inclusion criteria to maximize the benefit-risk profile.
  • For the upliFT-D trial for FTD, the company is focused on patient recruitment and expects to report initial safety and biomarker data in the second half of 2023.

3. Forward Guidance and Outlook:

• The company anticipates existing cash resources will fund operations into the first half of 2025.
• Key milestones for 2023 include:
  • Reporting initial safety and biomarker data from Cohort 4 of the Imagine-1 study by mid-2023.
  • Dosing the first GM1 patient at a higher dose in the second half of 2023.
  • Initial safety and biomarker data from the upliFT-D study expected in the second half of 2023.

4. Bad News, Challenges, or Points of Concern:

• The decline in cash reserves raises concerns about long-term funding and operational sustainability.
• The need to revise study inclusion criteria may indicate challenges in patient recruitment or optimizing treatment outcomes.
• Regulatory discussions regarding the registrational pathway for GM1 may delay timelines for pivotal studies, moving potential discussions to 2024.

5. Notable Q&A Insights:

• The company is confident in recruiting additional patients for the higher dose cohorts despite narrowing inclusion criteria.
• There is no specific threshold for beta-galactosidase activity established yet, but the focus will be on reducing GM1 ganglioside levels and improving clinical outcomes.
• The company is actively monitoring non-human primate supply chain issues but has not faced any impacts on preclinical programs to date.
• Initial data from the first cohort of the FTD trial will focus on safety and CSF progranulin levels, with expectations to achieve physiologic levels based on preclinical data.

Overall, while Passage Bio has made significant strides in its clinical programs, the financial outlook and operational challenges warrant close attention as they navigate the upcoming year.